|
|
Extramural Support
|
RMS2014 [E]
|
$298,831,922
|
$1,346,820
|
N/A
|
National Institutes of Health
|
|
|
Role of NFxB/HIF2a axis in renal cell carcinoma progression
|
5K08CA178168-02
|
$140,674
|
$140,674
|
ABEL, E
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
Exploiting mTORC1-driven cancer cell vulnerabilities
|
1F32CA177108-01A1
|
$55,094
|
$55,094
|
ACKERMAN, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
1U10CA180884-01
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
1U10CA180886-01
|
$26,616,497
|
$1,596,990
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S1
|
$79,593
|
$4,776
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S2
|
$208,457
|
$12,507
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S3
|
$229,232
|
$13,754
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S4
|
$1,163,256
|
$69,795
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S5
|
$1,543,656
|
$92,619
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S6
|
$265,465
|
$15,928
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S7
|
$3,000,000
|
$180,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
1U10CA180791-01
|
$737,200
|
$22,116
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
ATBC Study
|
ZIA CP010195 - 03031
|
$1,066,167
|
$63,970
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Sit
|
1U10CA180790-01
|
$1,439,850
|
$43,196
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
|
NCTN Deep South Research Consortium
|
1U10CA180855-01
|
$497,800
|
$12,445
|
ALVAREZ, RONALD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$709,489
|
$70,949
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
1U10CA180828-01
|
$656,150
|
$32,808
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-39S5
|
$10,116,159
|
$101,162
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-39S6
|
$75,000
|
$750
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-39S7
|
$122,667
|
$1,227
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
PHOTOACOUSTIC MICROSCOPY OF NEOVASCULARIZATION IN RENAL CANCER GROWTH AND THERAPY
|
5R01CA159959-04
|
$573,291
|
$573,291
|
ARBEIT, JEFFREY
|
WASHINGTON UNIVERSITY
|
|
|
Childhood Cancer Survivor Study
|
5U24CA055727-20
|
$4,071,218
|
$407,122
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
Identifying a Hypoxia Inducible Factor target profile in Renal Cell Carcinoma tum
|
5F31CA154080-04
|
$34,991
|
$34,991
|
ARREOLA, ALEXANDRA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
San Juan Minority-Based Community Clinical Oncology Program
|
3U10CA052667-23S1
|
$98,520
|
$3,941
|
BAEZ, LUIS
|
SAN JUAN HEALTH DEPARTMENT
|
|
|
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
|
1R01CA168621-01A1
|
$370,388
|
$370,388
|
BALACHANDRAN, SIDDHARTH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
|
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
|
ZIA BC 011232
|
$456,868
|
$45,687
|
Barchi, Joseph
|
CCR (NCI)
|
|
|
Clinical Studies to Circumvent Drug Resistance
|
ZIA BC 010620
|
$93,272
|
$23,318
|
Bates, Susan
|
CCR (NCI)
|
|
|
Investigation of the ABC Half-Transporter ABCG2
|
ZIA BC 010622
|
$139,909
|
$27,982
|
Bates, Susan
|
CCR (NCI)
|
|
|
Iowa Oncology Research Association
|
3U10CA035101-28S1
|
$123,717
|
$2,474
|
BEHRENS, ROBERT
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
|
Cancer Center Support Grant
|
3P30CA006516-49S1
|
$118,825
|
$1,188
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Cancer Center Support Grant
|
3P30CA006516-49S2
|
$75,000
|
$750
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Cancer Center Support Grant
|
3P30CA006516-49S3
|
$12,500
|
$125
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Cancer Center Support Grant
|
5P30CA006516-49
|
$10,827,666
|
$108,277
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Hawaii Minority-Based Clinical Community Oncology Program
|
3U10CA063844-20S1
|
$100,152
|
$2,003
|
BERENBERG, JEFFREY
|
UNIVERSITY OF HAWAII AT MANOA
|
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
1U10CA180847-01
|
$587,562
|
$29,378
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
1U10CA180821-01
|
$10,540,919
|
$210,818
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S1
|
$228,063
|
$4,561
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S2
|
$264,661
|
$5,293
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S3
|
$16,838
|
$337
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Development of Natural Product Leads as Anticancer Therapeutics
|
ZIA BC 011470
|
$238,328
|
$59,582
|
Beutler, John
|
CCR (NCI)
|
|
|
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
|
5K08CA138900-05
|
$169,560
|
$169,560
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
JHU ICMIC Program
|
5P50CA103175-09
|
$1,453,060
|
$29,061
|
BHUJWALLA, ZAVER
|
JOHNS HOPKINS UNIVERSITY
|
|
|
SWOG Network Group Operations Center of the NCTN
|
1U10CA180888-01
|
$13,829,118
|
$276,582
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
|
SWOG Community Clinical Oncology Program Research Base
|
3U10CA037429-29S2
|
$579,978
|
$23,199
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
|
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma
|
ZIA BC 011095
|
$102,756
|
$102,756
|
Bottaro, Donald
|
CCR (NCI)
|
|
|
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics
|
ZIA BC 011123
|
$77,067
|
$7,707
|
Bottaro, Donald
|
CCR (NCI)
|
|
|
Oncogenic Met Signaling in Urologic Malignancies
|
ZIA BC 011124
|
$333,956
|
$66,791
|
Bottaro, Donald
|
CCR (NCI)
|
|
|
Kidney Cancer GWAS
|
ZIA CP010187 - 10460
|
$5,328
|
$5,328
|
Brown, Kevin
|
DCEG (NCI)
|
|
|
Laboratory of Translational Genomics_Brown
|
ZIA CP010201 - 10570
|
$610,865
|
$61,086
|
Brown, Kevin
|
DCEG (NCI)
|
|
Total relevant funding to Kidney Disease for this search: $40,404,868
|
